JP2005514906A - ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法 - Google Patents

ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法 Download PDF

Info

Publication number
JP2005514906A
JP2005514906A JP2003502178A JP2003502178A JP2005514906A JP 2005514906 A JP2005514906 A JP 2005514906A JP 2003502178 A JP2003502178 A JP 2003502178A JP 2003502178 A JP2003502178 A JP 2003502178A JP 2005514906 A JP2005514906 A JP 2005514906A
Authority
JP
Japan
Prior art keywords
lce
assay
assay system
agent
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003502178A
Other languages
English (en)
Japanese (ja)
Inventor
フリードマン，ローリ
プラウマン，グレゴリー，ディー．
ベルビン，マーシャ
フランシス−ラング，ヘレン
リー，ダンクシー
フンケ，ロール，ピー．
カリーム，フェリックス，ディー．
キース，リンダ，エヌ．
コブリツェック，トーマス，アイ．
Original Assignee
エクセリクシス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセリクシス・インコーポレイテッド filed Critical エクセリクシス・インコーポレイテッド
Publication of JP2005514906A publication Critical patent/JP2005514906A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003502178A 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法 Withdrawn JP2005514906A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US32860501P 2001-10-10 2001-10-10
US35725302P 2002-02-15 2002-02-15
US36119602P 2002-03-01 2002-03-01
PCT/US2002/017739 WO2002099068A2 (fr) 2001-06-05 2002-06-03 Lce utilises comme modificateurs de la voie p53 et procede d'utilisation

Publications (1)

Publication Number Publication Date
JP2005514906A true JP2005514906A (ja) 2005-05-26

Family

ID=27501675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003502009A Withdrawn JP2004532638A (ja) 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＭＡＰ３Ｋｓおよび使用方法
JP2003502178A Withdrawn JP2005514906A (ja) 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003502009A Withdrawn JP2004532638A (ja) 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＭＡＰ３Ｋｓおよび使用方法

Country Status (5)

Country Link
EP (2) EP1402051A4 (fr)
JP (2) JP2004532638A (fr)
AU (1) AU2002314887A1 (fr)
CA (2) CA2449479A1 (fr)
WO (4) WO2002099068A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1572118A4 (fr) * 2002-12-20 2010-07-14 Millennium Pharm Inc Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883
DE10316701A1 (de) * 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
EP1657311A4 (fr) * 2003-07-11 2006-10-11 Banyu Pharma Co Ltd Methode d'evaluation de compose efficace dans le traitement de l'obesite
US20070087984A1 (en) * 2003-09-04 2007-04-19 Xiuyuan Hu Method of identifying agents that inhibit the growth of cancer cells
WO2005083425A2 (fr) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Agents de diagnostic et de therapie destines aux maladies associees a la proteine kinase 13 activee par un mitogene (map3k13)
EP2650907A3 (fr) 2004-06-04 2014-10-08 The Board of Trustees of the University of Illinois Procédés et dispositifs permettant de fabriquer et d'assembler des éléments à semiconducteur imprimables
KR101519038B1 (ko) 2007-01-17 2015-05-11 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 프린팅­기반 어셈블리에 의해 제조되는 광학 시스템
US8865489B2 (en) 2009-05-12 2014-10-21 The Board Of Trustees Of The University Of Illinois Printed assemblies of ultrathin, microscale inorganic light emitting diodes for deformable and semitransparent displays
US9442285B2 (en) 2011-01-14 2016-09-13 The Board Of Trustees Of The University Of Illinois Optical component array having adjustable curvature
WO2012158709A1 (fr) 2011-05-16 2012-11-22 The Board Of Trustees Of The University Of Illinois Barrettes de del à gestion thermique assemblées par impression
US8934965B2 (en) 2011-06-03 2015-01-13 The Board Of Trustees Of The University Of Illinois Conformable actively multiplexed high-density surface electrode array for brain interfacing
US9691873B2 (en) 2011-12-01 2017-06-27 The Board Of Trustees Of The University Of Illinois Transient devices designed to undergo programmable transformations
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572478B1 (fr) * 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Polypeptides et acides nucleiques de hbgad et higad et leur utilisation dans le traitement et le diagnostic de maladies associees a l'autoantigene gad.
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5554523A (en) * 1994-03-01 1996-09-10 Children's Hospital Of Philadelphia Nucleic acid sequences encoding human leucine-zipper protein-kinase
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
AU3354499A (en) * 1998-03-16 1999-10-11 Cadus Pharmaceutical Corporation Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
JP2002538826A (ja) * 1999-03-18 2002-11-19 ザ ユニバーシティ オブ ブリストル カエノラブジチス・エレガンス由来の多飽和脂肪酸（ｐｕｆａ）エロンガーゼ
JP2002542782A (ja) * 1999-04-23 2002-12-17 インサイト・ゲノミックス・インコーポレイテッド ヒト膜関連タンパク質
CA2342831A1 (fr) * 1999-07-22 2001-02-01 The University Of British Columbia Enzyme biosynthetique d'acides gras a chaines longues de plantes
CA2390421A1 (fr) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 24 proteines humaines secretees
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1299538A2 (fr) * 2000-06-20 2003-04-09 Incyte Genomics, Inc. Proteines secretees
AU9174501A (en) * 2000-08-11 2002-02-25 Merck Patent Gmbh Novel mitogen activated kinase
US7297523B2 (en) * 2000-11-29 2007-11-20 Xenon Pharmaceuticals Inc. Human elongase genes and uses thereof
WO2002063006A2 (fr) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Recepteurs et proteines associees aux membranes
WO2002062974A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine elongase hselo1
WO2002062975A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine du type elongase hselo1
WO2002096943A1 (fr) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Genes activant le stat6
AU2003231531A1 (en) * 2002-04-24 2003-11-10 Incyte Corporation Kinases and phosphatases

Also Published As

Publication number Publication date
CA2448112A1 (fr) 2002-12-12
WO2002098889A3 (fr) 2003-03-27
CA2449479A1 (fr) 2002-12-12
EP1402051A2 (fr) 2004-03-31
WO2002098468A1 (fr) 2002-12-12
EP1402262A4 (fr) 2005-05-11
WO2002099068A3 (fr) 2003-12-04
EP1402262A2 (fr) 2004-03-31
WO2002099068A2 (fr) 2002-12-12
JP2004532638A (ja) 2004-10-28
WO2002098891A3 (fr) 2003-05-30
AU2002314887A1 (en) 2002-12-16
EP1402051A4 (fr) 2005-08-17
WO2002098891A2 (fr) 2002-12-12
WO2002098889A2 (fr) 2002-12-12

Similar Documents

Publication Publication Date Title
US20050112568A1 (en) Dgks as modifiers of the p53 pathwha and methods of use
US20100325743A1 (en) Marks as modifiers of the p53 pathway and methods of use
US20060252035A1 (en) Sphks as modifiers of the p53 pathway and methods of use
JP2009082131A (ja) ｐ２１経路のモディファイヤーとしてのＨＡＤＨｓおよび使用方法
JP2005514906A (ja) ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法
JP2007502115A (ja) ＲＡＣ経路のモディファイヤーとしてのＭＥＬＫｓおよび使用方法
JP2005512529A (ja) βカテニン経路のモディファイヤーとしてのＴＡＯＪＩＫｓおよび使用方法
JP2004528045A (ja) ｐ５３経路のモディファイヤーとしてのＰ５ＣＲｓおよび使用方法
JP2007526746A (ja) ＰＴＥＮ経路のモディファイヤーとしてのＭＡＲＫｓおよび使用方法
JP2006513698A (ja) ｐ２１経路のモディファイヤーとしてのＦＬＪ２０６４７および使用方法
JP2005534324A (ja) ＡＸＩＮ経路のモディファイヤーとしてのＰＡＰＳＳｓおよび使用方法
JP2005506844A (ja) ｐ５３経路のモディファイヤーとしてのＬＲＲＣＡＰＳ及び使用方法
JP4646631B2 (ja) ＲＢ経路のモディファイヤーとしてのＣＣＴ６ｓおよび使用方法
JP2007502118A (ja) βカテニン経路のモディファイヤーとしてのＳＵＬＦｓ及び使用方法
US20070134732A1 (en) Lces as modifiers of the p53 pathway and methods of use
JP2005516583A (ja) ｐ５３経路のモディファイヤーとしてのＡＤＳＬｓおよび使用方法
US20050227228A1 (en) Map3ks as modifiers of the p53 pathway and methods of use
JP2005534335A (ja) Ｒｂ経路のモディファイヤーとしてのｐｓｍｃおよび使用方法
JP2005534334A (ja) ｐ２１経路のモディファイヤーとしてのＣＳＮＫ１ＧＳおよび使用方法
JP2006516096A (ja) ＲＡＣ経路のモディファイヤーとしてのＣＳＮＫｓおよび使用方法
JP2007516703A (ja) βカテニン経路のモディファイヤーとしてのＰＬＫｓ及び使用方法
JP2006517395A (ja) Ａｘｉｎ経路のモディファイヤーとしてのｆｌｊ１０６０７および使用方法
JP2005538723A (ja) ＣＨＫ経路のモディファイヤーとしてのＰＡＫｓおよび使用方法
AU2002303971A1 (en) LCEs as modifiers of the p53 pathway and methods of use
JP2007525964A (ja) ｐ５３経路のモディファイヤーとしてのＳＰＰＬｓおよび使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050526

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070308